Efficacy of dasatinib in a chronic myeloid leukemia patient with disease molecular relapse and chronic GVHD after haploidentical BMT: An immunomodulatory effect?

Bone Marrow Transplantation

Volumn 44, Issue 5, 2009, Pages 331-332

  Breccia, M ^a   Cannella, L ^a   Stefanizzi, C ^a   Carotti, A ^b   Santopietro, M ^a   Alimena, G ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; CYCLOSPORIN A; DASATINIB; HLA A2 ANTIGEN; HYDROXYUREA; IMATINIB; MERCAPTOPURINE;

ADULT; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RELAPSE; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; DISEASE COURSE; DONOR LYMPHOCYTE INFUSION; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; FEMALE; GENE MUTATION; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOMODULATION; LEUKOCYTOSIS; LIVER TOXICITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REPEATED DRUG DOSE; SPLENOMEGALY;

ADULT; BONE MARROW TRANSPLANTATION; COMBINED MODALITY THERAPY; FEMALE; GRAFT VS HOST DISEASE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RECURRENCE; THIAZOLES;

EID: 70349154648     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.20     Document Type: Article

References (8)

1. Hochhaus A, Baccarani M, Deininger M, Apperley J, Lipton JH, Goldberg SL et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukaemia in chronic phase with resistance or intolerance to imatinib. Leukemia 2008; 22: 1200-1206.
2. Kantarjian HM, Giles F, Quintas-Cardama A, Cortes J. Important therapeutic targets in chronic myelogenous leukaemia. Clin Cancer Res 2007; 13: 1089-1097.
3. Schade AE, Schieven GL, Townsend R, Jankowska AM, Susulic V, Zhang R et al. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood 2008; 111 1366-1377.
4. Seggewiss R, Lorè K, Greiner E, Magnusson MK, Price DA, Douek DC et al. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood 2005; 105: 2473-2479.
5. Ball LM, Egeler RM, EBMT Paediatric Working Party. Acute GVHD: pathogenesis and classification. Bone Marrow Transplant 2008; 41(Suppl 2): S58-S64.
6. Fei F, Yu Y, Schmitt A, Rojewski MT, Chen B, Greiner J et al. Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukaemia antigens. Exp Hematol 2008; 36: 1297-1308.
7. Mustjoki S, Ekblom M, Petteri Arstila T, Dybedal I, Epling-Burnette PK, Garzon F et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Blood 2008; 112: 215 (Abstract no. 573).
8. Nam S, Wiliams A, Vultur A, List A, Bhalla K, Smith D et al. Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukaemia cells. Mol Cancer Ther 2007; 6: 1400-1405.